ARTICLE | Clinical News
ALX-0171: Phase I/IIa data
May 23, 2016 7:00 AM UTC
Top-line data from 53 infants ages 1-24 months hospitalized for RSV infection in an international Phase I/IIa trial showed that once-daily inhaled ALX-0171 for 3 days met the primary safety endpoint. ...